Sanofi hands Regeneron $1.8B for new immuno-oncology pact

After winning approval for their PCSK9 drug Praluent last week, longtime partners Sanofi ($SNY) and Regeneron ($REGN) are back at it with a new collaboration. The French pharma giant will pay at least $1.8 billion in a new immuno-oncology deal that includes an early-stage checkpoint inhibitor. More from FierceBiotech